Olema Pharmaceuticals, Inc. (OLMA) Stock: Price, Forecast & Analyst Target
Olema Pharmaceuticals, Inc. (OLMA) — MoonshotScore 45/100 (Fair band), calculated Nov 18, 2026. Price $7.02 (-1.82%), as of the Nov 20, 2026 trading session; market cap $615M.
Educational signal · not a buy or sell recommendation · How to read this
Olema Pharmaceuticals, Inc. · OLMA · NASDAQ
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Olema Pharmaceuticals (OLMA)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, stalling growth and an expensive valuation, though the balance sheet is only middling, and the price trend has turned against it. Business Quality: Thin; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z 1.92 · Piotroski F 1
- ROE -69.8% · ROA -39.8% · current ratio 6.12
Holding back: weak fundamentals, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 46 | Fair | |
| 45 | Fair | |
| 45 | Fair | |
| 45 | Fair | |
| 45 | Fair | |
| 45 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $7.02 | |
| Change on the day | -1.82% | |
| 52-week range | $6.24 – $36.26 | |
| Market capitalisation | $615M | — |
| Shares traded on the day | 1.26M |
Price & events
Other perspectives
Council score for Olema Pharmaceuticals (OLMA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Olema Pharmaceuticals (OLMA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Olema Pharmaceuticals, Inc. (OLMA) is listed on NASDAQ. It employs 131 people and is led by Sean Bohen. The market values it at $615M.
What do the latest results show for Olema Pharmaceuticals (OLMA)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Olema Pharmaceuticals (OLMA)?
Short answer
What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z 1.92 · Piotroski F 1. Trailing ratios: ROE -69.8% · ROA -39.8% · current ratio 6.12.
Data-derived red flags
- Negative return on equity (-69.8%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Olema Pharmaceuticals (OLMA)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $2.25M · EPS -2.63 · 6 analysts. Current published price targets run low $20.00 · high $30.00 · consensus $25.00 · median $25.00 against a quoted price of $7.02 (as of Nov 20, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for OLMA.
Checked against the records this page reads, on the dates shown above.
How does Olema Pharmaceuticals compare with its peers?
Short answer
Olema Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $18.41 Nov 20, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $156.59 Nov 19, 2026 | $15.9B | 95 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $166.53 Nov 19, 2026 | $207B | 72 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $38.85 Nov 20, 2026 | $1.26B | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 66 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Olema Pharmaceuticals (OLMA) — this page | $7.02 | $615M | 45 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $20.00 – $30.00
- Consensus target
- $25.00
- Median target
- $25.00
- Revenue estimate
- $2.25M
- EPS estimate
- $-2.63
Consensus record · Captured .
Measured against a quoted price of $7.02 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 1, 2026
- Transactions
- 14
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 2
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held OLMA in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.19% | $8.53M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Olema Pharmaceuticals (OLMA)?
- Olema Oncology Announces Preclinical Data for KAT6A Degraders
- Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
- Olema Oncology to Participate in Upcoming Investor Conferences
- Olema Pharmaceuticals, Inc. Changes Corporate Name to Olema Oncology, Inc.
Olema Pharmaceuticals Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for OLMA?
OLMA carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is OLMA a good stock to buy?
Stock Expert AI does not rate OLMA buy, sell or hold. Olema Pharmaceuticals, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the OLMA stock price today?
The last price recorded for Olema Pharmaceuticals, Inc. (OLMA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the OLMA price target?
The analyst consensus price target for Olema Pharmaceuticals, Inc. (OLMA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for OLMA?
Olema Pharmaceuticals, Inc. (OLMA) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The company focuses on therapies for women's cancers, addressing a significant market need. Not financial advice.
How frequently does OLMA data refresh on this page?
OLMA's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven OLMA's recent stock price performance?
Olema Pharmaceuticals, Inc. (OLMA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OLMA overvalued or undervalued right now?
Olema Pharmaceuticals, Inc. (OLMA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of OLMA?
Fractional-share availability for Olema Pharmaceuticals, Inc. (OLMA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 10 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com